{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nalidixic root_protein_modifications_structuralModifications_structuralModificationType in Protein Structural Modification Type (approximate match)
Status:
US Approved Rx
(2019)
Source:
BLA761139
(2019)
Source URL:
First approved in 2019
Source:
BLA761139
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761121
(2019)
Source URL:
First approved in 2019
Source:
BLA761121
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2018)
Source:
BLA761108
(2018)
Source URL:
First approved in 2018
Source:
BLA761108
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2018)
Source:
BLA761092
(2018)
Source URL:
First approved in 2018
Source:
BLA761092
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2018)
Source:
BLA761102
(2018)
Source URL:
First approved in 2018
Source:
BLA761102
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2017)
Source:
NDA208743
(2017)
Source URL:
First approved in 2017
Source:
NDA208743
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Abaloparatide (brand name Tymlos) is a human parathyroid hormone related peptide [PTHrP(1-34)]
analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R).
This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys,
abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone
mineral content (BMC) that correlated with increases in bone strength at vertebral and/or
nonvertebral sites. Abaloparatide was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Status:
US Approved Rx
(2017)
Source:
BLA761061
(2017)
Source URL:
First approved in 2017
Source:
BLA761061
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA761033
(2016)
Source URL:
First approved in 2016
Source:
BLA761033
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA125521
(2016)
Source URL:
First approved in 2016
Source:
BLA125521
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA208583
(2016)
Source URL:
First approved in 2015
Source:
RYZODEG 70/30 by NOVO
Source URL:
Class:
PROTEIN
